

Fig. 1. Amino acid sequences of heat-stable enterotoxins produced by enteric bacteria. Common regions in all the sequences are boxed. Cited from a) Ref. 1, b) Ref. 2, c) Ref. 3, d) Ref. 4, and e) Ref. 5. The single letter notations of amino acid residues are according to *J. Biol. Chem.*, **261**, 1 (1986).

for analytical and preparative purposes in our laboratory. The abbreviations used in this paper are those recommended by the IUPAC-IUB [*J. Biol. Chem.*, **261**, 1 (1986)]. Additional abbreviations are: Ac_m, acetamidomethyl; HONSu, *N*-hydroxysuccinimide; DMF, *N,N*-dimethylformamide; MBzl, *p*-methylbenzyl; TFA, trifluoroacetic acid; TEA, triethylamine; DMSO, dimethyl sulfoxide.

General Procedures for Peptide Synthesis in Solution. As a typical procedure the coupling of compound **4** with compound **8** to give compound **9** is described as follows: Compound **4** (1.6 g, 0.75 mmol) was stirred with TFA (10 ml) at room temperature for 30 min and concentrated to a syrup. Meanwhile, compound **8** (0.82 g, 0.85 mmol) was dissolved in DMF (5 ml), cooled below -20°C , and mixed with 6.72 M HCl (1M=1 mol dm $^{-3}$) in dioxane (0.88 ml) and isopentyl nitrite (0.13 ml). The solution was stirred at -20°C for 25 min and mixed with a solution of the above syrup in DMF (10 ml) and TEA (0.94 ml). The mixture was further stirred at 0°C for 1 day. The precipitate formed in the reaction mixture was separated by filtration and the filtrate was concentrated to a syrup under reduced pressure. The syrup was triturated to a solid in chilled 0.1M HCl. The recrystallization of the solid from EtOH gave **9** (1.40 g).

The deprotection of Z groups, hydrazinolysis of peptide esters, and formation of peptide bonds by an active ester method were carried out as described previously.⁶⁾

Solid-Phase Peptide Synthesis. Peptide synthesis by the solid-phase method⁹⁾ was performed as described in a previous paper.⁷⁾

Removal of Protecting Groups by HF and Oxidation by Iodine. The protected peptides (25 μmol each) were treated with anhydrous liquid hydrogen fluoride¹⁰⁾ and air-oxidized as described previously.^{6c)} The solutions containing the air-oxidized peptides were partially concentrated by lyophilization and purified by HPLC, as described below. The purified peptides with an intramolecular disulfide bond(s) and Ac_m groups were oxidized by iodine at a peptide-to-iodine molar ratio of 1 : 40 in a mixture of MeOH and 0.1 M HCl as described in a previous paper.⁷⁾ The iodine-oxidized peptides were directly purified by HPLC, as described below.

High-Performance Liquid Chromatography (HPLC). The HPLC apparatus consisted of a Waters M600 multisolvent delivery system (Milford, MA) connected with a Hitachi UV 655A variable wavelength UV monitor and D-2000 chromatointegrator (Tokyo, Japan). The HPLC column was equilibrated with 10% CH₃CN in 0.05% TFA or 0.01M ammonium acetate (pH 5.7) and after injection of the sample solution, was developed with a linear gradient of 10–40% CH₃CN with increase in CH₃CN of 0.5 or 1% min $^{-1}$ at a flow rate of 2 ml min $^{-1}$. Eluates were monitored for absorption at 220 nm.

Amino Acid Analysis and Fast Atom Bombardment (FAB) Mass Spectrometry. The amino acid compositions and molecular weights of purified peptides were determined as described previously.³⁾

Biological Assay. Toxicity of synthetic peptides was assayed in suckling mice of 2 days old (1.7 \pm 0.1 g) as described previously.¹¹⁾

Results and Discussion

Previously,⁷⁾ to determine the mode of disulfide bond formation in ST_h (Fig. 7) we adopted a synthetic

procedure in which disulfide bonds in ST_h were formed stepwise and selectively using different types of removable protecting groups for Cys residues. We found that this synthetic procedure was suitable for determination of disulfide bond formation in ST_h. Therefore, in the present work we applied this procedure for determination of the positions of disulfide linkages in ST_p.

The three disulfide linkages in ST_h between Cys⁶ and Cys¹¹, Cys⁷ and Cys¹⁵, and Cys¹⁰ and Cys¹⁸, are shown in Fig. 7. These disulfide linkages were expected to be similar in ST_p, because the 13 amino acid sequence including 6 half Cys residues in ST_p differs only at Ala at the fourth position from the C-terminus from that in ST_h and has almost the same biological activity as the corresponding ST_h peptide. Accordingly, we synthesized three kinds of protected linear peptides with the segment from Cys⁵ to Cys¹⁷ of ST_p with two Cys residues at Cys⁵ and Cys¹⁰ or Cys⁶ and Cys¹⁴ or Cys⁹ and Cys¹⁷ protected by an Ac_m group and the other four Cys residues protected by an MBzl group, which correspond to the sequence from Cys⁶ to Cys¹⁸ in ST_h, as shown in Figs. 2–4. Table 1 summarizes data on protected peptides 1–21. The protected linear peptides thus obtained were treated with liquid




Fig. 2. Scheme for synthesis of a shorter peptide of ST_p linked by a disulfide bond between Cys⁵ and Cys¹⁰.




Fig. 3. Scheme for synthesis of a shorter peptide of ST_p linked by a disulfide bond between Cys⁹ and Cys¹⁷.




Fig. 4. Scheme for synthesis of a shorter peptide of ST_p linked by a disulfide bond between Cys⁶ and Cys¹⁴.

anhydrous hydrogen fluoride to remove all the protecting groups except Acm groups and air-oxidized to form intramolecular disulfide bonds between the four Cys residues, which had been protected by MBzl groups. The air-oxidized products were purified by HPLC on a reversed-phase column, as shown in Figs. 5a—5c. On the bases of amino acid and molecular weight analyses of the separated fractions, peptides with two disulfide bonds were concluded to be eluted in the peak fractions shown by asterisks (*) in Figs. 5a—5c. The yields of these peptides, for example those in Fig. 5a, were 14, 20, and 16% in order of their elution on the basis of the protected linear peptide. In this treatment, three kinds of peptides with two intramolecular disulfide bonds should theoretically be obtained. Figure 6 illustrates the HPLC profile of peak *2 in Fig. 5a, which was reduced by dithiothreitol and reoxidized spontaneously in air. Three peptide fractions were obtained similarly to those shown in Fig. 5a except for their peak ratios. However, peptides with a disulfide bond between two vicinal Cys residues were presumably formed with difficulty. In fact, when two disulfide bonds were formed in peptides 15 and 21, only two of three possible peptides could be isolated by

HPLC, as shown in Figs. 5b and 5c. The amino acid compositions, mass values, and biological activities of these peptides with two disulfide bonds are summarized in Table 2.

Then, these monomeric peptides with two disulfide bonds were selectively oxidized by iodine to form a third disulfide linkage at the two Cys residues that had been protected by Acm groups. The peptides with three disulfide linkages were separated and compared by HPLC with standard ST_p peptide, which consists of 13 amino acid residues including 6 Cys residues and has the same disulfide bond formation as native ST_p.^{6b)} Selective formation of a third disulfide bond between Cys⁵ and Cys¹⁰ or Cys⁹ and Cys¹⁷ in peptides *1 and *5 in Figs. 5a and 5b, respectively, yielded peptides that were identical with standard ST_p peptide on HPLC, as shown by arrows in Figs. 5e and 5f. Peptides *2, *3, and *4 in Figs. 5a and 5b, respectively, did not yield a peptide that was identical with standard ST_p peptide. The results indicated that the disulfide bonds in ST_p were linked between Cys⁵ and Cys¹⁰ and Cys⁹ and Cys¹⁷, and therefore that the remaining disulfide bond should be between Cys⁶ and Cys¹⁴. However, when the third disulfide bond was linked between Cys⁶

and Cys¹⁴ in two peptides *6 and *7 prepared from peptide **21** (Fig. 5c), no peptide was detected with the same retention time on HPLC as standard ST_p peptide. Figure 5g shows an HPLC profile of the peptide which was prepared by reaction of peptide *7 with iodine. Then, the three disulfide bonds were linked in reverse order; that is, we synthesized a protected linear peptide with two Cys residues at Cys⁶ and Cys¹⁴ protected by an MBzl group and the remaining four Cys residues protected by an Acn group by a solid-phase procedure. The first disulfide bond was formed between Cys⁶ and Cys¹⁴, and then the second and third disulfide bonds were formed between the remaining four Cys residues, as shown in Figs. 5d and 5h, respectively. When the peak fraction indicated by an asterisk in Fig. 5d was oxidized by iodine, the peak fraction *16 shown by an arrow in Fig. 5h was eluted in the same position as standard ST_p peptide by HPLC. The amino acid compositions and mass values of the peptides in the peak fractions shown by asterisks in Figs. 5e–5h are summarized in Table 3. The peptides eluted by HPLC in the same position as standard ST_p peptide shown in Figs. 5e, 5f, and 5h showed toxicities at doses of 0.8–1.0 ng/mouse, which were almost the same as that of standard ST_p peptide (0.7 ng), as described in Table 3. Thus, we concluded that the three intramolecular disulfide bonds of ST_p were between Cys⁵ and Cys¹⁰, Cys⁶ and Cys¹⁴, and Cys⁹ and Cys¹⁷, as shown in Fig. 7. Other disulfide bond linkages except

those described above were not examined, because the positions of the disulfide bonds of ST_p determined above were the same as those of ST_h.⁷⁾

When a third disulfide bond was linked between Cys⁵ and Cys¹⁰ and Cys⁹ and Cys¹⁷ in peptides *1 and *5 in Figs. 5a and 5b, respectively, they gave two peak fractions on HPLC, as shown in Figs. 5e and 5f, respectively. On HPLC one of them was eluted at the same position as standard ST_p peptide, while the other was eluted earlier. When a third disulfide bond was linked between Cys⁶ and Cys¹⁴ in peptide *7 in Fig. 5c, interestingly it gave only a peak fraction with the same retention time as peaks *9 and *11 in Figs. 5e and 5f, respectively. Moreover, these two peak fractions showed different circular dichroism spectra from each other in the range from 190 nm to 260 nm (not shown). These two peptides were not interconvertible, but stable on storage for a long time in a refrigerator. These findings suggested that two topologically stable and different conformers are present in peptides with the same three disulfide linkages and also that only one or both the two conformers are produced dependent upon the order of disulfide bond formation.

While peptide *1 was eluted as a single peak under the conditions for Fig. 5a, it was separated into two broad peak fractions on HPLC under different conditions from that in Fig. 5a, as depicted in Fig. 8. Each fraction showed the same profile on repeated HPLC as that before separation (not shown). Peptides in the

Table 1. Yields, Melting Points,^{a)} Solvents for Recrystallization, Optical Rotations, and Analytical Data of Intermediates

Compound	Yield	Mp θ _m /°C	Solvent for recrystallization	[α] _D ^{25 b)} degree	Found (%)			Calcd (%)		
	%				C	H	N	C	H	N
1	91.8	79–80	CHCl ₃ –hexane	–46.5						
2^{c)}	67.0	148–149	AcOEt–EtOH–ether	–70.5	52.65	6.77	12.27	52.82	6.71	12.32
3^{d)}	97.7	92–94	EtOH–ether	–64.3	50.21	6.87	15.53	50.17	6.80	15.49
4	93.1	169–171	EtOH–ether	–67.8	56.79	6.57	11.01	57.01	6.54	10.76
5^{e)}	94.1	126–127	AcOEt–hexane	–36.4	54.18	7.00	8.29	53.79	6.87	8.18
6	91.6	168–169	MeOH–ether	–23.8	51.13	6.86	13.52	51.45	6.87	13.64
7^{f)}	94.2	128–129.5	AcOEt–ether–hexane	–25.9	56.53	7.79	8.40	56.71	7.69	8.48
8^{g)}	94.7	148–149	MeOH–ether	–15.7	54.59	7.59	12.12	54.73	7.57	12.08
9	89.2	211–212	EtOH	–52.0 ^{h)}	57.14	6.99	10.42	57.35	6.74	10.70
10	88.1	94–95	AcOEt–hexane	–21.1	54.78	6.64	9.61	54.66	6.65	9.56
11	96.3	161–162	EtOH–ether	–18.1	56.49	6.61	9.80	56.89	6.60	9.76
12ⁱ⁾	70.5	152–153	EtOH–CHCl ₃ –ether	–59.0	52.64	6.82	12.21	52.82	6.71	12.32
13^{j)}	90.5	105–106	EtOH–ether	–43.8	49.97	6.85	16.00	50.17	6.80	15.49
14	83.3	177–178	EtOH	–60.2	54.25	6.43	12.10	54.77	6.42	12.17
15	83.8	225 (decomp)	EtOH	–64.2 ^{h)}	57.02	6.77	10.67	57.35	6.74	10.70
16	62.7		MeOH–ether	–6.1	44.13	7.25	18.50	44.55	7.21	18.56
17	89.4	148–149	AcOEt–hexane	–23.1	56.72	6.63	9.69	56.89	6.60	9.76
18	92.2	170–172	EtOH	–64.1	56.68	6.48	10.81	57.01	6.54	10.76
19	82.8	163–164.5	MeOH–ether	–16.6	49.56	7.83	16.06	49.04	8.22	15.40
20	84.1	202–203	EtOH–AcOEt	–47.7 ^{k)}	56.21	6.82	11.26	56.10	6.83	11.03
21	84.5	197–198	EtOH	–59.6 ^{h)}	55.80	6.46	11.32	56.07	6.57	10.90

a) Melting points were uncorrected. b) *c*=1.0 in DMF. c) Boc-Cys(MBzl)-Cys(Acn)-Asn-Pro-Ala-OMe. d) Boc-Cys(MBzl)-Cys(Acn)-Asn-Pro-Ala-N₂H₃. e) Boc-Cys(Acn)-Cys(MBzl)-OMe. f) Boc-Cys(Acn)-Cys(MBzl)-Glu(OBu^t)-Leu-OEt. g) Boc-Cys(Acn)-Cys(MBzl)-Glu(OBu^t)-Leu-N₂H₃. h) *c*=0.5 in DMSO. i) Boc-Cys(Acn)-Cys(MBzl)-Asn-Pro-Ala-OMe. j) Boc-Cys(Acn)-Cys(MBzl)-Asn-Pro-Ala-N₂H₃. k) *c*=1.0 in DMSO.




Fig. 5. HPLC profiles of: a) a deprotected and air-oxidized solution of peptides with two disulfide bonds at four Cys residues other than Cys⁵ and Cys¹⁰ (Fig. 2), b) a deprotected and air-oxidized solution of peptides with two disulfide bonds at four Cys residues other than Cys⁹ and Cys¹⁷ (Fig. 3.), c) a deprotected and air-oxidized solution of peptides with two disulfide bonds at four Cys residues other than Cys⁶ and Cys¹⁴ (Fig. 4), d) a deprotected and air-oxidized solution of a peptide with a disulfide bond between Cys⁶ and Cys¹⁴, e) an I₂-oxidized solution of peak *1 in a), f) an I₂-oxidized solution of peak *5 in b), g) an I₂-oxidized solution of peak *7 in c), and h) an I₂-oxidized solution of peak *8 in d). Peaks *10, *12, and *16 shown by arrows were eluted at the same retention time as standard ST_p peptide.




Fig. 6. HPLC profile of peptide *2 in Fig. 5a, which was reduced and reoxidized by air. Peaks a, b, and c had the same retention times as those of peaks *1, *2, and *3 in Fig. 5a, respectively.

two peak fractions 1 and 2 shown in Fig. 8 were oxidized by iodine immediately after their elution from an HPLC column. The peptide in the first fraction gave two peaks like that shown in Fig. 9a, one of which was identical with standard ST_p peptide, whereas the peptide in the second fraction gave only a peptide that was not identical with standard ST_p peptide, as shown in Figs. 9b and 9c, respectively. These findings suggested that peptide *1 consisted of two components, which were rapidly interconvertible and therefore were in equilibrium. These peptides are presumed to be two conformers with cis and trans configurations around the peptide bond between Asn¹¹ and Pro¹², one of them corresponding to a peptide in the first fraction, and the other to a peptide in the second fraction in Fig. 8. One of the two conformers yielded two peptides, and the other only one peptide, when they were oxidized by iodine. Since peptide *5 gave two peak fractions on treatment with iodine (Fig. 5f), it was considered to consist of two components like peptide *1. However, peptide *5 could not be separated by HPLC under the same conditions as for peptide *1 in Fig. 8. The two conformers in peptide *1 might have dissimilar physicochemical properties and those in peptide *5 similar properties, or they might be rapidly equilibrated, because on reversed-phase HPLC peptide *1 could be separated but peptide *5 could not be separated.

Houghten et al.¹²⁾ proposed the mode of disulfide bond formation of ST_p from an experiment on the reoxidation kinetics of ST_p, which they synthesized according to the amino acid sequence proposed previously,¹³⁾ although the amino acid sequence was later revised to the sequence shown in Fig. 1.²⁾ The pro-

formation of ST_h produced by a human strain of enterotoxigenic *E. coli*, as shown in Fig. 7, and also of ST_p produced by *Vibrio-mimicus*.⁵⁾ The positions of the disulfide linkages were identical with those of ST_p examined in this work. These results imply that the three dimensional structure in the common 13 amino acid region as shown in Fig. 1 is very similar in all ST's examined to date. Further elucidation of this spatial structure should be useful in understanding the structure-activity relation of ST and its mechanism of binding to receptor proteins on the membranes of




Fig. 8. HPLC profile of peptide *1 in Fig. 5a eluted with a linear-gradient of 10–30% CH_3CN concentration with increase in CH_3CN of $0.5\% \text{ min}^{-1}$ in 0.01 M ammonium acetate (pH 5.7).

intestinal cells.

This work was supported in part by a Scientific Research Grant (No. 62470022 to Y. S.) from the Ministry of Education, Science and Culture and in part by a grant from the Naito Foundation. We are indebted to Mrs. Noriko Mizoguchi for amino acid analysis and also to Mrs. Aiko Kobatake for elemental analysis and preparation of the manuscript.

References

- 1) S. Aimoto, T. Takao, Y. Shimonishi, S. Hara, T. Takeda, Y. Takeda, and T. Miwatani, *Eur. J. Biochem.*, **129**, 257 (1982).
- 2) a) T. Takao, T. Hitouji, S. Aimoto, Y. Shimonishi, S. Hara, T. Takeda, Y. Takeda, and T. Miwatani, *FEBS Lett.*, **152**, 1 (1983); b) M. R. Thompson and R. A. Giannella, *Infect. Immun.*, **47**, 834 (1985).
- 3) T. Takao, N. Tominaga, Y. Shimonishi, S. Hara, T. Inoue, and A. Miyama, *Biochem. Biophys. Res. Commun.*, **125**, 845 (1984); T. Takao, N. Tominaga, S. Yoshimura, Y. Shimonishi, S. Hara, T. Inoue, and A. Miyama, *Eur. J. Biochem.*, **152**, 199 (1985).
- 4) T. Takao, Y. Shimonishi, M. Kobayashi, O. Nishimura, M. Arita, T. Takeda, T. Honda, and T. Miwatani, *FEBS Lett.*, **193**, 250 (1985).
- 5) T. Takao, Y. Hidaka, M. Kobayashi, O. Nishimura, M. Arita, T. Takeda, H. Imaishi, T. Honda, T. Miwatani, and Y. Shimonishi, the manuscript in preparation.
- 6) a) S. Yoshimura, T. Takao, H. Ikemura, S. Aimoto, Y. Shimonishi, S. Hara, T. Takeda, Y. Takeda, and T. Miwatani, *Bull. Chem. Soc. Jpn.*, **57**, 1381 (1984); b) S. Yoshimura, H. Ikemura, H. Watanabe, S. Aimoto, Y. Shimonishi, S. Hara, T. Takeda, T. Miwatani, and Y. Takeda, *FEBS Lett.*, **181**, 138 (1985); c) H. Ikemura, S. Yoshimura, S.




Fig. 9. HPLC profile of peak fractions eluted in Fig. 8 and oxidized by iodine: a) a mixture of peak fractions 1 and 2, b) peak fraction 1, and c) peak fraction 2. Peaks shown by arrows had the same retention times as standard ST_p peptide.

Aimoto, Y. Shimonishi, S. Hara, T. Takeda, Y. Takeda, and T. Miwatani, *Bull. Chem. Soc. Jpn.*, **57**, 2550 (1984).

7) Y. Shimonishi, Y. Hidaka, M. Hane, M. Koizumi, S. Aimoto, T. Takeda, T. Miwatani, and Y. Takeda, *FEBS Lett.*, **215**, 165 (1987).

8) S. Yoshimura and Y. Shimonishi, *Bull. Chem. Soc. Jpn.*, **58**, 2805 (1985).

9) R. B. Merrifield, *J. Am. Chem. Soc.*, **85**, 2149 (1963).

10) S. Sakakibara, Y. Shimonishi, Y. Kishida, M. Okada, and H. Sugihara, *Bull. Chem. Soc. Jpn.*, **40**, 2164 (1967).

11) Y. Takeda, T. Takeda, T. Yano, K. Yamamoto, and T. Miwatani, *Infect. Immun.*, **25**, 978 (1979).

12) R. A. Houghten, J. M. Ostresh, and F. A. Klipstein, *Eur. J. Biochem.*, **145**, 157 (1984).

13) S. K. Chan and R. A. Giannella, *J. Biol. Chem.*, **256**, 7744 (1981).